According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled Trial
A multi-center, double-blind, placebo-controlled RCT in UK adults aged 40–70, randomly assigning participants to receive 0mg, 10mg, 20mg, 40mg, or 80mg of atorvastatin daily, with all-cause mortality as the primary endpoint over a minimum 5-year follow-up, and stratification by baseline cardiovascular risk to ensure health-matching. Prospective Cohort Study with Dose-Response Analysis
A prospective cohort study of 100,000+ UK adults aged 40–70 with baseline health records, tracking atorvastatin prescription doses (0, 10, 20, 40, 80mg) over 10 years, using time-varying exposure modeling and health-matched controls via inverse probability weighting to estimate hazard ratios for all-cause mortality across dose levels. Nested Case-Control Study within Cohort
A nested case-control study within a UK primary care database, identifying all-cause mortality cases aged 40–70 and matching each to 5 controls by age, sex, comorbidities, and baseline cardiovascular risk, then comparing prior atorvastatin exposure (dose and duration) to assess odds ratios for mortality across dose tiers. Cross-Sectional Analysis with Dose Stratification
A cross-sectional analysis of mortality data linked to prescription records in a UK population sample aged 40–70, stratifying by current atorvastatin dose and adjusting for confounders, to observe if mortality rates form a J-shaped pattern across dose levels. Ecological Study of Population-Level Dose Trends
An ecological study comparing regional variations in atorvastatin prescribing patterns (average daily dose) across UK regions with regional all-cause mortality rates in adults aged 40–70 to detect a J-shaped association.